FIBROBIOLOGICS doses first patients in diabetic foot ulcer trial

June 16, 2026 8:30 AM

FibroBiologics, Inc. (NASDAQ: FBLG) announced that the first patients have been dosed in its Phase 1/2 clinical trial evaluating CYWC628 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found